As we continue to improve our understanding of cancer biology, one thing remains a game-changer for cancer care: the ability to detect cancer in from a liquid biopsy.
Just a few years ago, the idea of having a non-invasive diagnostic test for cancer seemed out of reach, but as technology progressed to detect rare cell types in a sample – the liquid biopsy was born. With applications from early cancer detection, patient monitoring and aiding oncologists where surgical biopsy is difficult – the promise that liquid biopsies could transform cancer care is endless.
The two most well-developed biomarkers for liquid biopsies, circulating tumour cells (CTCs) and circulating cell-free DNA (ctDNA) are subject to challenges in the pre-analytical and analytical steps. The research community is coming together to prove the utility of these tests to get liquid biopsies into the hands of more clinicians.
Join us for Liquid Biopsy ONLINE – a virtual 4-part series where we dive into the technology that is on the brink of transforming cancer care.
Each session will be one hour long and will be at 3pm BST/ 4pm CET/ 10am ET
Webinar 1: The future of liquid biopsy: clinical utility
Thursday 1st October – 3pm BST/ 4pm CET/ 10am EST
As the research community comes together to prove the clinical utility of liquid biopsy – a few challenges remain, including a lack of standard protocol and proving utility.
Join us for this interactive global panel discussion on overcoming the challenges and pitfalls of current liquid biopsy utility and what is needed to increase clinical use.
This webinar will be an interactive discussion with:
Lauren Leiman, Executive Director, BloodPac
Klaus Pantel, Chairman of the Institute of Tumour Biology, The University Medical Centre Hamburg-Eppendorf
Matthias Muester, Medical Director, AmoyDx
Catherine Alix-Panabieres, Director of Laboratory of Rare Human Circulating Cells, The University of Montpellier
Jonathan Beer, Director of Disruptive technologies, Novartis
Valerie Taly, Group Leader, INSERM
Webinar 2: Isolating rare events in blood
Thursday 8th October – 3pm BST/ 4pm CET/ 10am EST
Another of the major challenges in liquid biopsy is the reliability of the results. Isolating and measuring CTCs or ctDNA is technically challenging, with high false-negative results a concern for oncologists.
Join us as we dive into leading case studies of practices to isolate rare events in blood and how this can inform clinicians in decision making.
Speakers:
Detection of viable CTCs at the single-cell level: The EPIDROP technology.- Catherine Alix-Panabieres, Director of Laboratory of Rare Human Circulating Cells, The University of Montpellier
An Integrative approach to studying RNA and DNA of CTCS from a single sample – Evi Lianidou, Professor, University of Athens
Developing strategies to ensure reliability of ctDNA results for clinical applications – Valerie Taly, Group Leader, INSERM
Webinar 3: Liquid Biopsy in a clinical setting
Thursday 15th October – 3pm BST/ 4pm CET/ 10am EST
It is already documented that CTCs and ctDNA are relevant for different cancer types, but to prove their utility, more large-scale liquid biopsy trials are needed.
This webinar will bring us case studies and results of major liquid biopsy clinical trials.
Speakers:
“Liquid Biopsy – From Discovery to clinical implementation” – Klaus Pantel, Chairman of the Institute of Tumour Biology at the University Medical Centre Hamburg-Eppendorf
“ctDNA to assist phase 1 clinical trial selection” – Caroline Dive, Deputy Director, CRUK Manchester Institute
“PADA-1, a clinical utility trial on ESR1 mutations detection in metastatic breast cancer: design and first results” – Francois Clement Bidard, Head of Breast Cancer Group, Institut Curie
“Seeking signals in blood using liquid biopsies” – Heidi Maria Namløs, Postdoctoral Fellow in Cancer Genomics, Oslo University Hospital
Webinar 4: From FFPE to Liquid Biopsy: Applications for MicroSatellite Instability (MSI) Testing Now and in the Future.
Thursday 22nd October – 3pm BST/ 4pm CET/ 10am EST
Microsatellite instability testing measures the ability of a cell to repair mistakes in DNA replication. Recently, MSI status has been associated as a biomarker for immunotherapy response, and thus serves as a key indicator for immunotherapy research.
Join us for this webinar, where we explore the clinical utility of MSI testing.
Precision Oncology for Immune Checkpoint Inhibitor Therapy with OncoMate MSI Dx System. – Jeff Bacher, Sr Research Scientist 2, Promega
Clinical Utility of MSI testing for Lynch syndrome and anti-PD1 immunotherapy: The Pathologists Perspective. – Dr. Anca Oniscu, Consultant Pathologist and Clinical Lead for Molecular Pathology, Laboratory Medicine, Edinburgh Royal Infirmary.
Image credit: Background photo created by kjpargeter – www.freepik.com
Speakers
Klaus Pantel, Chairman of the Institute of Tumour Biology, The University Medical Centre Hamburg-Eppendorf
Lauren Leiman, Executive Director, BloodPac
Matthias Mueser, Medical Director, AmoyDx
Valerie Taly, Group Leader, INSERM
Catherine Alix-Panabieres, Director of Laboratory of Rare Human Circulating Cells, The University of Montpellier
Jonathan Beer, Director of Disruptive technologies, Novartis
